FDA Approves Lisraya (Brepocitinib) as First Oral JAK Inhibitor for Adult Dermatomyositis, Efficacy & Safety Confirmed in Phase 3 Trial of 241 Patients

September 6, 2026

FDA USA

Overview

The US FDA has approved Lisraya (brepocitinib) tablets as the first oral treatment for adult dermatomyositis. Granted Orphan Drug and Priority Review designations, this JAK pathway inhibitor effectively reduces inflammation in muscles and skin. Its efficacy and safety were validated in a Phase 3 study involving 241 adult patients, offering a groundbreaking oral therapeutic option for this rare and debilitating disease.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has announced the approval of Lisraya (generic name: brepocitinib) tablets, marking the first oral treatment specifically indicated for adult dermatomyositis. This approval represents a significant breakthrough, substantially expanding the therapeutic options for patients suffering from this rare and debilitating autoimmune disease.

Technical / Clinical Details

Mechanism of Action: Lisraya (brepocitinib) is an oral small-molecule inhibitor of the Janus Kinase (JAK) pathway. The JAK pathway plays a crucial role in cytokine signaling and acts as a central driver of inflammatory responses in autoimmune diseases. By inhibiting the JAK pathway, Lisraya effectively suppresses the inflammatory processes that lead to muscle and skin damage in dermatomyositis.
Clinical Trial Results: The efficacy and safety of Lisraya were evaluated in a Phase 3 multicenter, placebo-controlled study involving 241 adult patients with dermatomyositis. The trial demonstrated that patients in the Lisraya arm achieved a statistically significant improvement in the primary endpoint, a measure of disease activity score, compared to the placebo group. The safety profile was manageable, with good tolerability observed even when compared to existing immunosuppressive agents.
Approval Pathway and Designations: Lisraya had previously received “Orphan Drug” designation for dermatomyositis, recognizing its potential to treat a rare disease. Furthermore, due to the high unmet medical need, it was granted “Priority Review” designation, facilitating its expedited approval process.

Background & Context

Dermatomyositis is one of a group of autoimmune inflammatory muscle diseases characterized by distinct skin rashes and muscle weakness. Severe cases can lead to dysphagia, respiratory complications, and even interstitial lung disease, significantly impairing patients’ quality of life. Current treatments have primarily relied on corticosteroids and other immunosuppressants, which often come with significant side effects and challenges in long-term management.

The approval of the first oral therapy is expected to significantly enhance treatment convenience for patients, leading to improved adherence and better long-term disease control.

Strategic Significance & Outlook

The approval of Lisraya has the potential to transform the treatment paradigm for adult dermatomyositis. As an oral medication, it offers greater ease of administration, which should facilitate better patient adherence and improved long-term disease control. This success could also accelerate the development of JAK inhibitors for other rare autoimmune diseases. Moreover, brepocitinib’s approval reaffirms the broad therapeutic potential of JAK inhibitors and solidifies its position as a new treatment option in disease areas with high unmet needs.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.